Médicaments en développement en 2009 pour les cancers de l'ovaire
SciMedWeb
● Ǻ6 Phase II
● abagovomab (anti-idiotype ovarian cancer vaccine) Phase II/III
● Abraxane (albumin-bound paclitaxel) Phase II
● Advexin (contusugene ladenovec) Phase I
● AE-37 Phase I
● AG-14699 Phase II
● AGS-8M4 Phase I
● Alimta (pemetrexed) Phase II
● AMG 386 Amgen Phase II
● ANZ-207 Phase I
● Armala (pazopanib) Phase II
● Avastin (bevacizumab) Phase III
● AZD2281 Phase II
● AZD6244 Phase II
● belinostat Phase II
● BMS-753493 (epothilone-folate)
● BSI-201 Phase II
● catumaxomab Phase II
● CDX-1307 Phase I
● D4064A Phase I
● DCVax-L (ovarian cancer vaccine) Phase I/II
● denenicokin (interleukin-21) Phase I/II
● EC-145 Phase II
● EGEN 001 Phase I
● Elacyt (elacytarabine) Phase II
● enzastaurin (LY317615) Phase II
● eribulin mesylate (E7389) Phase II
● farletuzumab (MORAb-003) Phase II/III
● Herceptin (trastuzumab) Phase II
● Hycamtin (topotecan) Phase III
● iboctadekin Phase I
● idronoxil Phase III
● IMC-1121B Phase II
● IMT-1012 Phase I
● IT-101 Phase II
● Karenitecin (cositecan) Phase III
● lapuleucel-T Phase I
● Leukine (sargramostim) Phase II
● MK-4827 Phase I
● MORAb-009 Phase I
● NKTR-102 Phase II
● NOV-002 Phase II
● oglufanide Phase II
● OGX-427 Phase I
● Opaxio (paclitaxel polyglumex) Phase III
● OvaRex (oregovomab) Phase III
● OVax (ovarian cancer vaccine) Phase I/II
● patupilone (EPO906) Phase III
● perifosine Phase I
● pertuzumab Phase II
● plevitrexed (BGC 9331) Phase II
● Quinamed (amonafide) Phase II
● sagopilone Phase I/II
● SNS-595 Phase II
● systemic hedgehog antagonist Phase II
● tasisulam Phase II
● Telcyta (canfosfamide) Phase III
● topotecan liposomal Phase I
● tucotuzumab (celmoleukin) Phase II
● volociximab Phase II
● Yondelis (trabectedin)
● Zybrestat (fosbretabulin) Phase II
● ZYC300 Phase I
InTextoResearch, Baelen, Liège, Wallonie (Wallonia), Belgique
(Belgium) & Agence Wallonne d’Information Scientifique (AWIS) (Marc
Lacroix, scim...@mail.com)